Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Meanwhile, another busy day is unfolding here on the Pharmalot campus, where we are mulling over our calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. So time to get cracking. On that note, here are a few items of interest for you to peruse as your journey begins. Hope you have a productive day and, as always, do keep in touch. …
The two Food and Drug Administration officials in charge of leading reviews of Covid-19 vaccine applications will leave the agency this fall, STAT tells us. Marion Gruber and Phil Krause, collectively have more than 42 years of experience at the FDA and their high-profile departures sparked questions about whether it would affect FDA work during the pandemic. One reason they are leaving is disagreement with the Biden administration over the use of Covid-19 booster shots, according to The New York Times.
A bill proposed by U.S. Senate Democrats aimed at lowering prescription drug prices may not apply to the millions of people who get health insurance through their jobs, prompting alarm from employers and progressive groups, The Hill reports. The measure would allow the secretary of Health and Human Services to negotiate lower drug prices for Medicare. By contrast, a House measure would apply those lower negotiated prices not only to seniors on Medicare, but also to the roughly 150 million Americans who get health insurance through their employers.
Create a display name to comment
This name will appear with your comment